Bicycle Therapeutics (BCYC) Assets Average (2019 - 2026)

Bicycle Therapeutics (BCYC) has 8 years of Assets Average data on file, last reported at $629.5 million in Q2 2026.

• Quarterly Assets Average fell 26.64% year-over-year to $629.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $629.5 million (down 26.64% YoY) and the FY2025 annual result came in at $837.2 million, up 7.88% from the prior year.
• Assets Average retreated to $629.5 million in Q2 2026, from $685.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.0 billion in Q3 2024 to a low of $413.9 million in Q4 2022.
• A 5-year average of $655.6 million and a median of $623.3 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average jumped 143.99% — and 2026, when it decreased 26.64%.
• Tracing BCYC's Assets Average over 5 years: stood at $413.9 million in 2022, then jumped by 49.08% to $617.0 million in 2023, then jumped by 58.31% to $976.8 million in 2024, then retreated by 24.16% to $740.8 million in 2025, then decreased by 15.02% to $629.5 million in 2026.
• The last three Assets Average figures came in at $629.5 million (Q2 2026), $685.0 million (Q1 2026), and $740.8 million (Q4 2025), per Business Quant data.